Nucor earnings beat by $0.08, revenue fell short of estimates
Joseph W. LaPlume, Executive Vice President of Corporate Strategy and Development at Charles River Laboratories International, Inc. (NYSE:CRL), has recently sold 4,400 shares of the company’s common stock. The transaction, dated February 20, 2025, was executed at a price of $162.50 per share, totaling approximately $715,000. This insider sale comes at a time when InvestingPro data shows management has been actively buying back shares, suggesting continued corporate confidence in the company’s value. The stock, currently trading near $163, has seen a -32.7% decline over the past year. Following this sale, LaPlume retains ownership of 20,013 shares in the company. Charles River Laboratories, with a market capitalization of $8.3 billion, is a leading provider of essential products and services to enable drug discovery and development. According to InvestingPro analysis, the company appears undervalued based on its Fair Value estimate, with analysts maintaining a moderate buy consensus. For deeper insights into CRL’s valuation and insider trading patterns, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Charles River Laboratories reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $2.66, compared to the forecasted $2.54. The company’s revenue also exceeded projections, reaching $1 billion against the anticipated $985.18 million. These results reflect a strong performance despite ongoing challenges in the biopharmaceutical demand environment. Evercore ISI revised its price target for Charles River Labs to $175 from $195, maintaining an "In Line" rating, acknowledging the company’s realistic outlook for 2025. The firm highlighted Charles River Labs’ cost-cutting initiatives and share repurchase strategies as part of its long-term structural changes. For 2025, Charles River Laboratories anticipates a 3.5% to 5.5% organic revenue decline, with non-GAAP EPS expected to range between $9.10 and $9.60. The company plans to repurchase approximately $350 million in stock, aiming to enhance shareholder value amid pricing headwinds. Operational restructuring is projected to save $225 million annually by 2026, positioning the company to capitalize on future market opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.